findmyKOL
Clinical trialNCT00960557CompletedPhase 1Interventional

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden

SponsorMateon TherapeuticsEnrollment16Neoplasm Metastasis
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Oxigene Investigational Site

    Westmead, New South Wales, Australia

  • Oxigene Investigational Site

    South Brisbane, Queensland, Australia

  • Oxigene Investigational Site

    Adelaide, South Australia, Australia

  • Oxigene Investigational Site

    Bentleigh, Victoria, Australia

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2009
Primary completion
31 Oct 2010
Completion
31 Oct 2010
Last update posted
23 Aug 2011
Registered enrollment
16
Registry id
NCT00960557
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.